Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.

@article{Lopes2017IntracranialHI,
  title={Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.},
  author={Renato D Lopes and Patr{\'i}cia Oliveira Guimar{\~a}es and Bradley J. Kolls and Daniel M. Wojdyla and Cheryl D Bushnell and Michael G. Hanna and J. Donald Easton and Laine E Thomas and Lars Wallentin and Sana M. Al-Khatib and Claes Held and Pedro Gabriel Melo de Barros E Silva and John Hunter Alexander and Christopher B. Granger and Hans-Christoph Diener},
  journal={Blood},
  year={2017},
  volume={129 22},
  pages={2980-2987}
}
We investigated the frequency and characteristics of intracranial hemorrhage (ICH), the factors associated with the risk of ICH, and outcomes post-ICH overall and by randomized treatment. We identified patients with ICH from the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who received ≥1 dose of the study drug (n = 18 140). ICH was adjudicated by a central committee. Cox regression models were used to… CONTINUE READING

5 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy .
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy .
We identified patients with ICH from the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who received ≥1 dose of the study drug ( n = 18 140 ) .
We identified patients with ICH from the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who received ≥1 dose of the study drug ( n = 18 140 ) .
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
Independent factors associated with increased risk of ICH were enrollment in Asia or Latin America , older age , prior stroke / transient ischemic attack , and aspirin use at baseline .
This highlights the clinical relevance of reducing ICH by using apixaban rather than warfarin and avoiding concomitant aspirin , especially in patients of older age .
Apixaban resulted in significantly less ICH ( 0.33% per year ) , regardless of type and location , than warfarin ( 0.80% per year ) .
ICH occurred at a rate of 0.80% per year with warfarin regardless of INR control and at a rate of 0.33% per year with apixaban and was associated with high short - term morbidity and mortality .
Apixaban resulted in significantly less ICH ( 0.33% per year ) , regardless of type and location , than warfarin ( 0.80% per year ) .
This highlights the clinical relevance of reducing ICH by using apixaban rather than warfarin and avoiding concomitant aspirin , especially in patients of older age .
ICH occurred at a rate of 0.80% per year with warfarin regardless of INR control and at a rate of 0.33% per year with apixaban and was associated with high short - term morbidity and mortality .
All Topics